Your browser doesn't support javascript.
loading
Antibody conversion rates to SARS-CoV-2 in saliva from children attending summer schools in Barcelona, Spain.
Dobaño, Carlota; Alonso, Selena; Fernández de Sevilla, Mariona; Vidal, Marta; Jiménez, Alfons; Pons Tomas, Gemma; Jairoce, Chenjerai; Melé Casas, María; Rubio, Rocío; Hernández García, María; Ruiz-Olalla, Gemma; Girona-Alarcón, Mònica; Barrios, Diana; Santano, Rebeca; Mitchell, Robert A; Puyol, Laura; Mayer, Leonie; Chi, Jordi; Rodrigo Melero, Natalia; Carolis, Carlo; Garcia-Miquel, Aleix; Bonet-Carne, Elisenda; Claverol, Joana; Cubells, Marta; Fortuny, Claudia; Fumadó, Victoria; Jou, Cristina; Muñoz-Almagro, Carmen; Izquierdo, Luis; Bassat, Quique; Gratacós, Eduard; Aguilar, Ruth; García-García, Juan José; Moncunill, Gemma; Jordan, Iolanda.
Afiliação
  • Dobaño C; ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain. carlota.dobano@isglobal.org.
  • Alonso S; CIBER de Enfermedades Infecciosas, Madrid, Spain. carlota.dobano@isglobal.org.
  • Fernández de Sevilla M; Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. carlota.dobano@isglobal.org.
  • Vidal M; ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Jiménez A; Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
  • Pons Tomas G; Institut de Recerca Sant Joan de Déu, Esplugues, Barcelona, Spain.
  • Jairoce C; Pediatrics Department, Hospital Sant Joan de Déu, Universitat de Barcelona, Esplugues, Barcelona, Spain.
  • Melé Casas M; ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Rubio R; ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Hernández García M; Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
  • Ruiz-Olalla G; Pediatrics Department, Hospital Sant Joan de Déu, Universitat de Barcelona, Esplugues, Barcelona, Spain.
  • Girona-Alarcón M; ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Barrios D; Pediatrics Department, Hospital Sant Joan de Déu, Universitat de Barcelona, Esplugues, Barcelona, Spain.
  • Santano R; ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Mitchell RA; Pediatrics Department, Hospital Sant Joan de Déu, Universitat de Barcelona, Esplugues, Barcelona, Spain.
  • Puyol L; ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Mayer L; Institut de Recerca Sant Joan de Déu, Esplugues, Barcelona, Spain.
  • Chi J; Paediatric Intensive Care Unit, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain.
  • Rodrigo Melero N; ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Carolis C; ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Garcia-Miquel A; ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Bonet-Carne E; ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Claverol J; ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Cubells M; ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Fortuny C; Biomolecular Screening and Protein Technologies Unit, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Fumadó V; Biomolecular Screening and Protein Technologies Unit, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Jou C; Fetal Medicine Research Center (Hospital Clínic and Hospital Sant Joan de Déu), Universitat de Barcelona, Barcelona, Spain.
  • Muñoz-Almagro C; Fetal Medicine Research Center (Hospital Clínic and Hospital Sant Joan de Déu), Universitat de Barcelona, Barcelona, Spain.
  • Izquierdo L; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Bassat Q; Universitat Politècnica de Catalunya, BarcelonaTech, Barcelona, Spain.
  • Gratacós E; Institut de Recerca Sant Joan de Déu, Esplugues, Barcelona, Spain.
  • Aguilar R; Fundació Sant Joan de Déu, Barcelona, Spain.
  • García-García JJ; Institut de Recerca Sant Joan de Déu, Esplugues, Barcelona, Spain.
  • Moncunill G; Fundació Sant Joan de Déu, Barcelona, Spain.
  • Jordan I; Institut de Recerca Sant Joan de Déu, Esplugues, Barcelona, Spain.
BMC Med ; 19(1): 309, 2021 11 23.
Article em En | MEDLINE | ID: mdl-34809617
ABSTRACT

BACKGROUND:

Surveillance tools to estimate viral transmission dynamics in young populations are essential to guide recommendations for school opening and management during viral epidemics. Ideally, sensitive techniques are required to detect low viral load exposures among asymptomatic children. We aimed to estimate SARS-CoV-2 infection rates in children and adult populations in a school-like environment during the initial COVID-19 pandemic waves using an antibody-based field-deployable and non-invasive approach.

METHODS:

Saliva antibody conversion defined as ≥ 4-fold increase in IgM, IgA, and/or IgG levels to five SARS-CoV-2 antigens including spike and nucleocapsid constructs was evaluated in 1509 children and 396 adults by high-throughput Luminex assays in samples collected weekly in 22 summer schools and 2 pre-schools in 27 venues in Barcelona, Spain, from June 29th to July 31st, 2020.

RESULTS:

Saliva antibody conversion between two visits over a 5-week period was 3.22% (49/1518) or 2.36% if accounting for potentially cross-reactive antibodies, six times higher than the cumulative infection rate (0.53%) assessed by weekly saliva RT-PCR screening. IgG conversion was higher in adults (2.94%, 11/374) than children (1.31%, 15/1144) (p=0.035), IgG and IgA levels moderately increased with age, and antibodies were higher in females. Most antibody converters increased both IgG and IgA antibodies but some augmented either IgG or IgA, with a faster decay over time for IgA than IgG. Nucleocapsid rather than spike was the main antigen target. Anti-spike antibodies were significantly higher in individuals not reporting symptoms than symptomatic individuals, suggesting a protective role against COVID-19.

CONCLUSION:

Saliva antibody profiling including three isotypes and multiplexing antigens is a useful and user-friendlier tool for screening pediatric populations to detect low viral load exposures among children, particularly while they are not vaccinated and vulnerable to highly contagious variants, and to recommend public health policies during pandemics.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Adult / Child / Child, preschool / Female / Humans País/Região como assunto: Europa Idioma: En Revista: BMC Med Assunto da revista: MEDICINA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Adult / Child / Child, preschool / Female / Humans País/Região como assunto: Europa Idioma: En Revista: BMC Med Assunto da revista: MEDICINA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Espanha